CVRx, Inc. (CVRX)

Market Cap	203.65M -37.9%
Revenue (ttm)	56.65M +10.4%
Net Income	-53.31M
EPS	-2.04
Shares Out	26.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	234,952
Open	7.25
Previous Close	7.16
Day's Range	7.06 - 7.91
52-Week Range	4.30 - 11.30
Beta	1.12
Analysts	Buy
Price Target	11.20 (+44.7%)
Earnings Date	May 7, 2026

About CVRX

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 30, 2021
• Employees: 223
• Stock Exchange: NASDAQ
• Ticker Symbol: CVRX
• Website: https://www.cvrx.com

Financial Performance

In 2025, CVRx, Inc.'s revenue was $56.65 million, an increase of 10.45% compared to the previous year's $51.29 million. Losses were -$53.31 million, -11.10% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for CVRX stock is "Buy." The 12-month stock price target is $11.2, which is an increase of 44.70% from the latest price.

Price Target

$11.2

(44.70% upside)

Analyst Consensus: Buy